首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >ADX47273 (S-(4-fluoro-phenyl)-{3-(3-(4-fluoro-phenyl)-(1,2,4)-oxadiazol-5-yl)-piperidin-1- yl}-methanone): a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activiti
【24h】

ADX47273 (S-(4-fluoro-phenyl)-{3-(3-(4-fluoro-phenyl)-(1,2,4)-oxadiazol-5-yl)-piperidin-1- yl}-methanone): a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activiti

机译:ADX47273(S-(4-氟苯基)-{3-(3-(4-氟苯基)-(1,2,4)-恶二唑-5-基)-哌啶-1-基}-甲酮) :一种新型的代谢型谷氨酸受体5-选择性正变构调节剂,具有临床前抗精神病样和认知激活作用

获取原文
获取原文并翻译 | 示例
           

摘要

Positive allosteric modulators (PAMs) of metabotropic glutamate receptor subtype 5 (mGlu5) enhance N-methyl-d-aspartate receptor function and may represent a novel approach for the treatment of schizophrenia. ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-y l}-methanone], a recently identified potent and selective mGlu5 PAM, increased (9-fold) the response to threshold concentration of glutamate (50 nM) in fluorometric Ca(2+) assays (EC(50) = 170 nM) in human embryonic kidney 293 cells expressing rat mGlu5. In the same system, ADX47273 dose-dependently shifted mGlu5 receptor glutamate response curve to the left (9-fold at 1 microM) and competed for binding of [(3)H]2-methyl-6-(phenylethynyl)pyridine (K(i) = 4.3 microM), but not [(3)H]quisqualate. In vivo, ADX47273 increased extracellular signal-regulated kinase and cAMP-responsive element-binding protein phosphorylation in hippocampus and prefrontal cortex, both of which are critical for glutamate-mediated signal transduction mechanisms. In models sensitive to antipsychotic drug treatment, ADX47273 reduced rat-conditioned avoidance responding [minimal effective dose (MED) = 30 mg/kg i.p.] and decreased mouse apomorphine-induced climbing (MED = 100 mg/kg i.p.), with little effect on stereotypy or catalepsy. Furthermore, ADX47273 blocked phencyclidine, apomorphine, and amphetamine-induced locomotor activities (MED = 100 mg/kg i.p.) in mice and decreased extracellular levels of dopamine in the nucleus accumbens, but not in the striatum, in rats. In cognition models, ADX47273 increased novel object recognition (MED = 1 mg/kg i.p.) and reduced impulsivity in the five-choice serial reaction time test (MED = 10 mg/kg i.p.) in rats. Taken together, these effects are consistent with the hypothesis that allosteric potentiation of mGlu5 may provide a novel approach for development of antipsychotic and procognitive agents.
机译:代谢型谷氨酸受体亚型5(mGlu5)的正变构调节剂(PAM)增强N-甲基-d-天冬氨酸受体的功能,可能代表一种新型的精神分裂症治疗方法。 ADX47273 [S-(4-氟-苯基)-{3- [3-(4-氟-苯基)-[1,2,4]恶二唑-5-基]-哌啶-1-基}-甲酮],最近确定的有效和选择性的mGlu5 PAM,在表达人胚肾293细胞的荧光Ca(2+)测定(EC(50)= 170 nM)中对谷氨酸阈值浓度(50 nM)的响应增加(9倍)大鼠mGlu5。在同一系统中,ADX47273剂量依赖性地将mGlu5受体谷氨酸响应曲线向左移动(在1 microM时为9倍),并竞争[[3)H] 2-甲基-6-(苯基乙炔基)吡啶(K( i)= 4.3 microM),但不等于[(3)H] quisqualate。在体内,ADX47273增加了海马和前额叶皮层中细胞外信号调节激酶和cAMP响应元件结合蛋白的磷酸化,这两者对于谷氨酸介导的信号转导机制至关重要。在对抗精神病药物治疗敏感的模型中,ADX47273降低了大鼠条件回避反应[最小有效剂量(MED)= 30 mg / kg ip],降低了小鼠阿扑吗啡诱导的爬升(MED = 100 mg / kg ip),对刻板印象或僵直症。此外,ADX47273在小鼠中阻断了苯环利定,阿扑吗啡和苯丙胺诱导的运动活性(MED = 100 mg / kg i.p.),并降低了伏隔核中而不是纹状体中多巴胺的细胞外水平。在认知模型中,ADX47273增加了五种选择系列反应时间测试(MED = 10 mg / kg i.p.)在大鼠中的新物体识别(MED = 1 mg / kg i.p.)并降低了冲动性。综上所述,这些作用与以下假设相符:mGlu5的变构增强作用可能为抗精神病药和促认知药的发展提供一种新颖的方法。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号